Key Insights

Highlights

Success Rate

86% trial completion

Published Results

31 trials with published results (15%)

Research Maturity

99 completed trials (47% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

7.6%

16 terminated out of 210 trials

Success Rate

86.1%

-0.4% vs benchmark

Late-Stage Pipeline

6%

12 trials in Phase 3/4

Results Transparency

31%

31 of 99 completed with results

Key Signals

31 with results86% success16 terminated

Data Visualizations

Phase Distribution

143Total
Not Applicable (53)
Early P 1 (4)
P 1 (48)
P 2 (26)
P 3 (11)
P 4 (1)

Trial Status

Completed99
Recruiting33
Unknown27
Active Not Recruiting20
Terminated16
Not Yet Recruiting7

Trial Success Rate

86.1%

Benchmark: 86.5%

Based on 99 completed trials

Clinical Trials (210)

Showing 20 of 20 trials
NCT05589714Recruiting

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

NCT06574997UnknownPrimary

Expanded Access Program for RP in Adults

NCT05926583Phase 3Active Not RecruitingPrimary

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

NCT05573984Active Not RecruitingPrimary

Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

NCT06912633Phase 2RecruitingPrimary

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

NCT02617966Recruiting

Rod and Cone Mediated Function in Retinal Disease

NCT01432847Recruiting

Cell Collection to Study Eye Diseases

NCT07502664RecruitingPrimary

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

NCT06292650Early Phase 1RecruitingPrimary

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

NCT06388200Phase 3Active Not RecruitingPrimary

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

NCT04127006Active Not RecruitingPrimary

Rate of Progression in EYS Related Retinal Degeneration

NCT05537220Phase 3Active Not RecruitingPrimary

Oral N-acetylcysteine for Retinitis Pigmentosa

NCT02086890Not ApplicableActive Not RecruitingPrimary

Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa

NCT06517940Active Not RecruitingPrimary

A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)

NCT05909488Phase 2Not Yet RecruitingPrimary

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

NCT05786287Not Yet RecruitingPrimary

Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa

NCT06460844Phase 1Active Not RecruitingPrimary

Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

NCT07408232Phase 1RecruitingPrimary

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

NCT04765345Active Not Recruiting

Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

NCT01736059Phase 1Active Not Recruiting

Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

Scroll to load more

Research Network

Activity Timeline